HLA Typing Market Research Report Information By Technology (Molecular Assay Technologies, Non-molecular Assay Technologies), By Product & Service (Reagents & Consumables, Instruments, Software & Services), By Application (Diagnostic Applications, Research Applications, Donor-recipient cross-matching, Infectious disease testing, Cancer diagnosis & prevention, Transfusion therapy, Other diagnostic applications), By End-user (Commercial service providers, Hospitals & surgical centers, Research laboratories & academic institutes), And By Regio

Global HLA Typing Market Overview

The HLA Typing Market Size was valued at USD 1.5 Billion in 2022. The HLA Typing market industry is projected to grow from USD 1.6 Billion in 2023 to USD 2.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.00% during the forecast period (2024 - 2032). The growing prevalence of long-term illnesses and the increased need for organ transplants are the key market drivers boosting the expansion of the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Thermo Fisher Scientific announced in August 2024 that its SeCore CDx HLA Sequencing System has been granted 510(k) clearance from the FDA. This type of system is very important for the use of TECELRA® – a new T-cell receptor therapy to treat certain types of cancer, including synovial sarcoma, through the use of companion diagnostics. Such a clearance highlights the place of high-resolution HLA typing in the treatment of patients with certain tumor characteristics thereby showing the increasing scope of HLA typing in personalized medicine.

HLA Typing Market Trends

• Growing need for organ transplants is driving the market growth

Market CAGR for HLA Typing is being driven by the rising number of organ transplants. Human Leukocyte Antigen typing, or HLA typing, is a crucial procedure in organ and tissue transplantation that establishes the compatibility of the recipient and donor. The proteins called HLA molecules, which are present on the surface of cells, help the immune system distinguish between self and non-self-cells. A close match between the recipient's and donor's HLA types lowers the possibility of transplant rejection.

Additionally, the demand for HLA typing to reduce the risk of graft rejection and immunosuppressant has increased due to the rising  burden of chronic diseases, including acute and chronic hepatitis, coronary artery disease, end-stage renal disease, chronic kidney disease, and chronic renal disease among people of all ages. Using DNA-based molecular diagnostic techniques, HLA typing looks for each individual's unique set of HLA antigens. HLA matching lowers the risk of graft-versus-host disease and increases the production of new, healthy blood cells. Over the course of the projected period, this is anticipated to fuel market expansion. Furthermore, throughout the course of the forecast period, rising demand for organ transplants due to an increase in end-stage diseases among the elderly population is anticipated to drive market expansion.

Rising organ transplant demand brought on by an increase in organ failure instances as a result of unhealthy lifestyles, binge drinking, and drug abuse is anticipated to further propel market revenue growth. The HLA typing for the transplant market is strongly impacted by the rising demand for organ transplants. Investments in cutting-edge HLA typing technology have been fueled by the need for exact HLA matching to increase transplant success rates. Comprehensive HLA profiling can be achieved by the use of high-throughput sequencing and other molecular approaches. High-throughput simultaneous screening of numerous genes is made possible by next-generation sequencing (NGS) technologies, which also dramatically lower consumable costs. However, the entire sequencing procedure, from sample preparation to data archiving, is usually expensive and time-consuming.

For instance, the number of kidney, liver, and heart transplants that occurred in the United States in 2021 was 90,483, 11,891, 3,502, and 24,670, 9,236, and 3,817, respectively, according to organdonor.gov, which was last updated in March 2022. Due to the enormous volume of organ transplants performed in hospitals, HLA typing tests will consequently be used more frequently, which will fuel the expansion of this market. Thus, result in driving the HLA Typing market revenue.

HLA Typing Market Segment Insights

HLA Typing Technology Insights

The HLA Typing market segmentation, based on Technology, includes Molecular Assay Technologies and Non-molecular Assay Technologies. The molecular assay technologies segment dominated the market. This is because of their great sensitivity and specificity; molecular tests make it possible to identify infectious diseases early on and diagnose them accurately. For the purpose of starting the right therapy and stopping future transmission, a timely diagnosis is crucial. Molecular tests are useful tools for the targeted identification of bacteria, viruses, fungi, and parasites, as well as for epidemiological research and treatment planning.

HLA Typing Product & Service Insights

The HLA Typing market segmentation, based on Product & Service, includes Reagents & Consumables, Instruments, and Software & Services. The instruments generated the most income. This is because of their increased affordability and usefulness. With the introduction of cutting-edge technologies, better, more precise instruments with longer shelf lives have been created. Additionally, it is anticipated that technological advancements in HLA typing would have a major impact on this segment's revenue growth.

HLA Typing Application Insights

The HLA Typing market segmentation, based on Application, includes Diagnostic Applications, Research Applications, Donor-recipient cross-matching, Infectious disease testing, Cancer diagnosis & prevention, Transfusion therapy and other diagnostic applications. The diagnostic applications generated the most income. This is because the diagnosis of uncommon and chronic disorders with HLA typing is becoming more common. The growing frequency of preimplantation genetic diagnosis using HLA typing and the increasing frequency of CKD, thalassemia, and other chronic illnesses are driving up the need for HLA matching bone marrow and kidney transplants.

HLA Typing End-user Insights

The HLA Typing market segmentation, based on End-user, includes Commercial service providers, Hospitals & surgical centers and Research laboratories & academic institutes. The hospitals & surgical centers generated the most income. This is due to the growing number of transplant procedures carried out in hospitals and the expanding patient pool. The need for HLA typing has been increased by the rising number of solid organ, bone marrow, and tissue transplants performed in hospitals, and this trend is predicted to continue. Furthermore, hospitals' modern healthcare infrastructure and highly qualified staff are important contributors to the segment's revenue growth.

Figure 1:  HLA Typing Market, by End-user, 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

HLA Typing Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American HLA Typing market area will rule this market, owing to an increase in the number of organ transplant procedures performed, and the strong presence of important players in the area will boost market growth in this region.

Further, the major countries investigated in the market report are the US, Germany, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure 2:  HLA TYPING MARKET SHARE BY REGION 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe HLA Typing market has the second-largest portion of the market due to the increased efficiency, speed, and accuracy of HLA typing testing. Further, the German HLA Typing market had the biggest market share, and the UK HLA Typing market was the European market with the quickest rate of growth.

The Asia-Pacific HLA Typing Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to the improved infrastructure of healthcare facilities and thoughtfully crafted reimbursement policies. Moreover, China’s HLA Typing market had the biggest market share, and the Indian HLA Typing market was the Asia-Pacific market with the quickest rate of growth.

HLA Typing Key Market Players & Competitive Insights

Leading market players are putting a lot of money into R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, HLA Typing industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  HLA Typing industry to help customers and expand the market segment. In recent years, the HLA Typing industry has provided some of the biggest benefits to medicine. Major players in the HLA Typing market, including Bio-Rad Laboratories, Inc (US), F Hoffmann-La Roche Ltd (Switzerland), QIAGEN V (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux SA (France), are engaging in research and development activities in an effort to boost market demand.

American company Bio-Rad Laboratories, Inc. develops and produces specialized technology products for the clinical diagnostics and life science research industries. The company was founded in Berkeley, California, in 1952 by married University of California, Berkeley students David and Alice Schwartz. The headquarters of the multinational corporation Bio-Rad are in Hercules, California. In March 2023, Bio-Rad was given the iQ-Check kits that the company sells, approved by AOAC International and AFNOR for use with the CFX Opus Deep well Real-time PCR System.

Known by most as Roche, F. Hoffmann-La Roche AG is a multinational healthcare corporation based in Switzerland that operates in two divisions, diagnostics and pharmaceuticals. Shares of Roche Holding AG, its parent firm, are traded in the SIX Swiss exchanges. The company's Basel headquarters are situated there. Based on revenue, Roche ranks as the fifth-biggest pharmaceutical corporation ly. In August 2022, Roche created a brand-new computerized Light Cycler technology to assist in identifying cancer in patients.

Key Companies in the HLA Typing market include

• Bio- Rad Laboratories, Inc (US)


• F Hoffmann-La Roche Ltd (Switzerland)


• QIAGEN V (Netherlands)


• Thermo Fisher Scientific Inc. (US)


• bioMérieux SA (France)

HLA Typing Industry Developments

April 2021: In order to support businesses and academic institutions working on HLA applications in vaccine and drug development, CareDx, Inc., a leading precision medicine company concentrated on the discovery, development, and commercialization of healthcare solutions for transplant patients, announced the launch of a fully functional next-generation sequencing (NGS) HLA typing service in Sweden.

September 2020: Leading provider of molecular diagnostics, Omixon, introduced OmniType, a software package and 11-locus multiplex HLA genotyping assay compatible with Illumina® sequencing systems. With the help of the product, a variety of samples can be processed in just one working day, going from gDNA to a library that is ready for sequencing in just six hours.

HLA Typing Market Segmentation

HLA Typing Technology Outlook

• Molecular Assay Technologies


• Non-molecular Assay Technologies

HLA Typing Product & Service Outlook

• Reagents & Consumables


• Instruments


• Software & Services

HLA Typing Application Outlook

• Diagnostic Applications


• Research Applications


• Donor-recipient cross-matching


• Infectious disease testing


• Cancer diagnosis & prevention


• Transfusion therapy


• Other diagnostic applications

HLA Typing End-user Outlook

• Commercial service providers


• Hospitals & surgical centers


• Research laboratories & academic institutes

HLA Typing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America